Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Close of up of an older woman's eye | Image credit: Syda Productions - stock.adobe.com
First Aflibercept Biosimilars Approved in US

May 20th 2024

The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). (aflibercept). However, patent litigation has left it unclear when the biosimilars will come to market.

AJMC
Budget Impact Analysis of Biosimilar Natalizumab in the US

May 17th 2024

Woman sitting on bed with back pain illustrated by a highlighted spine | Image credit: WavebreakMediaMicro - stock.adobe.com
Radiographic Progression Low for High-Risk Patients With axSpA on Both Secukinumab and an Adalimumab Biosimilar

April 12th 2024

FDA approval stamp in red | Image credit: chrisdorney - stock.adobe.com
FDA Approves First 2 Denosumab Biosimilars

March 5th 2024

Doctor stacking wooden blocks with health care icons | image credit: REDPIXEL - stock.adobe.com
Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024

January 14th 2024

Continuing Medical Education
May 29th 2024

Managed Care Pharmacy: A Plan for the Future and How Pharmacists Are Leading the Way

0.5 Credits / General Pharmacy

More News

Screenshot of Margaret Rehayem of National Alliance of Healthcare Purchaser Coalitions
April 20th 2023

There Remains a Need to Educate Employers, Employees on Biosimilars: Margaret Rehayem

Laura Joszt, MA
While employers fall on a spectrum when it comes to knowledge and understanding of biosimilars, there does remain a need to educate them, as well as for them to educate their employees, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.
Screenshot of Margaret Rehayem of National Alliance of Healthcare Purchaser Coalitions
April 13th 2023

Margaret Rehayem Highlights Strategies From the Employer Playbook on Biosimilars

Laura Joszt, MA
The Employer Playbook on Biosimilars highlights strategies employers can use to navigate challenges around ensuring employee access to biosimilars at the pharmacy, as well as how to respond to pharmacy benefit managers who aren’t making biosimilars available on the formulary, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.
Kathy Oubre, MS, CEO of Pontchartrain Cancer Center
April 12th 2023

Kathy Oubre Discusses Challenges With PBMs and Payers in the Biosimilar Market

Pearl Steinzor
Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discusses the use of biosimilars and how pharmacy benefit managers (PBMs) as well as payers have challenged the biosimilar market.
cutting costs visualized by someone cutting a price tag in half
April 10th 2023

Biosimilars Can Create Huge Savings, but Interchangeability Needs to Be Reviewed

Laura Joszt, MA
A new report from AHIP indicates that biosimilars have the potential to garner savings of $180 billion over 5 years, but there needs to be a review of the approval process for interchangeability to encourage more approvals.
Man hand holding dollar sign: © andranik123 - stock.adobe.com
April 8th 2023

Biosimilars Are Mighty, Can Help Alleviate Drug Spend Cost Burden

Maggie L. Shaw
With the global market for biologics estimated at $382 billion just last year, and a projected global drug spend of close to $1.5 trillion by 2027, the landscape is ripe for biosimilars to help decrease the health care system’s cost burden.
Canada on a globe with a green pin | Image Credit: © zerophoto - adobe.stock.com
April 1st 2023

More Canadian Jurisdictions Implement Mandatory Biosimilar Switching Policies

Laura Joszt, MA
The province of Newfoundland and Labrador and the territory of Yukon both announced biosimilar switching policies, bringing Canada to a total of 10 out of 13 jurisdictions have a policy in place.
Brown skin | Image credit: © PixieMe - adobe.stock.com
March 29th 2023

AAD Posters Address Misconceptions, Concerns Regarding Biosimilar Use in Dermatology

Laura Joszt, MA
Two posters presented at the American Academy of Dermatology (AAD) annual meeting evaluated misconceptions and addressed concerns around the use of biosimilars in dermatology.
FDA image
March 24th 2023

FDA Approves Sandoz’ High-Concentration Version of Adalimumab Biosimilar, Hyrimoz

Allison Inserro
Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).
rendering of a biosimilar molecule
March 18th 2023

Biosimilars May Not Be Cheap, but Are "Helping to Make Cancer Therapies More Accessible," Expert Says

Alana Hippensteele
Biosimilars may not be perfect, but they are, at the very minimum, helping to make cancer therapies a little bit more accessible, said Andre D. Harvin, PharmD, MS, executive director of pharmacy, oncology, Cone Health.
Site Logo
March 13th 2023

Neulasta Onpro: A Coup de Grâce?

Chelsee J. Jensen, PharmD, BCPS Caleb J. Scheckel, DO Ronald S. Go, MD Aakash Desai, MBBS, MPH Scott A. Soefje, PharmD
With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.
Stethoscope on financial papers | photo credit: shahrilkhmd - stock.adobe.com
March 9th 2023

Employer Playbook Suggests Strategies for Biosimilar Adoption, Navigating Adalimumab Launches

Laura Joszt, MA
A new resource from the National Alliance of Healthcare Purchaser Coalitions aims to help plan sponsors adopt biosimilars into their pharmacy benefit plans.
Image representing biosimilars: hafakot - stock.adobe.com
March 8th 2023

New WHO Biosimilar Guidelines Aim to Streamline, Clarify Regulations

Jared Kaltwasser
The new recommendations from the World Health Organization (WHO) urge viewing the totality of evidence when evaluating biosimilar products.
AJMC The Center for Biosimilar logo
March 4th 2023

Biosimilar News Round-up: Insulin Biosimilar Discount, Infliximab Adherence, and More

AJMC Staff
A roundup of the latest biosimilar news from The Center for Biosimilars®.
identical vials in a row
February 26th 2023

Gastroenterologists, Rheumatologists Cite Greatest Familiarity With Biosimilars

Laura Joszt, MA
A Cardinal Health report reviewed the potential impact biosimilars will have in rheumatology, gastroenterology, dermatology, and ophthalmology.
PA Is Part of an “Antiquated System” With Patient Safety, Workforce Burnout Implications
February 21st 2023

PA Is Part of an “Antiquated System” With Patient Safety, Workforce Burnout Implications

Laura Joszt, MA
close up of a closed eye
February 20th 2023

Retinal Physicians Report Reservations Around Ophthalmology Biosimilars

Laura Joszt, MA
There are 2 ranibizumab biosimilars approved in the United States, and with more ranibizumab and the first aflibercept biosimilars on the horizon, gaps in knowledge among retinal physicians should be addressed.
rendering of a molecule
February 16th 2023

The Growing Wave of Biosimilars for Autoimmune Diseases

Laura Joszt, MA
When the first adalimumab (Humira) biosimilar launched at the end of January, it was just the beginnings of a wave of coming biosimilars for anti-inflammatory biologics.
Site Logo
February 8th 2023

Humira: The First $20 Billion Drug

Jason B. Gibbons, PhD Micaela Laber, MPH, MBA Charles L. Bennett, MD, PhD, MPP
The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
rows of identical vials
January 31st 2023

First Humira Biosimilar, Amjevita, Launches in the United States

Laura Joszt, MA
The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, Humira.
stethoscope on top of money
January 27th 2023

Drug Prices to Continue Upward Trend Even as Biosimilars Enter the Market

Laura Joszt, MA
Multiple adalimumab biosimilars will hit the US market in 2023, but the drug is still projected to have the largest price increase for the calendar year starting July 1.
intravenous drip
January 21st 2023

Sintilimab Plus Bevacizumab Biosimilar Improves Response Rates, Depth of Response in HCC

Laura Joszt, MA
Compared with sorafenib, a combination of sintilimab and a bevacizumab biosimilar improved responses in patients with unresectable hepatocellular carcinoma (HCC).
Ken Cohen interview
January 18th 2023

Dr Ken Cohen Discusses the Role of Prior Authorizations in Value-Based Care

Laura Joszt, MA Justina Petrullo
Ken Cohen, MD, director of translational research for Optum Care, talks about the value of prior authorizations in different contexts, and how simplicity can benefit the process in some situations.
Cost of biologics
January 17th 2023

Biosimilar Competition to Herceptin Helped Reduce Price of All Forms of Trastuzumab

Allison Inserro
close up of a closed eye
January 14th 2023

With 2 Biosimilars Available, Use Remains Low Among Ophthalmologists

Laura Joszt, MA
Two ranibizumab biosimilars launched in the United States in 2022, but a new report shows comfort and familiarity with biosimilars has gone down compared with a year ago.
Screenshot of Ken Cohen, MD, from a video interview
January 6th 2023

Dr Ken Cohen Speaks on the Impact of Market Power on Biosimilar Uptake

Justina Petrullo Laura Joszt, MA
Ken Cohen, MD, director of translational research for Optum Care, speaks on the future of more biosimilars hitting the market, and how they will influence value-based care.
close up of money
January 1st 2023

PBMs Announce 2023 Coverage Plans for Adalimumab Biosimilars

Laura Joszt, MA
The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved interchangeable biosimilar.
Top 5 Most-Read AJMC® Journal Articles of 2022
December 25th 2022

Top 5 Most-Read AJMC® Journal Articles of 2022

Christina Mattina
In 2022, the articles published in the peer-reviewed The American Journal of Managed Care® (AJMC®) explored care management interventions, savings from biosimilars, and much more.
Biosimilars Are a "Wonderful" Option for Patients With Cancer, Says Susan Sabo-Wagner
December 23rd 2022

Biosimilars Are a "Wonderful" Option for Patients With Cancer, Says Susan Sabo-Wagner

Justina Petrullo Allison Inserro
Biosimilars are a wonderful option for patients, but the growing number available can be challenging to manage when different payers prefer different agents, said Susan Sabo-Wagner, MSN, RN, OCN, executive director of clinical strategy for Oncology Consultants of Houston, Texas.
Top 5 Most Popular Biosimilars Content of 2022
December 20th 2022

Top 5 Most Popular Biosimilars Content of 2022

Laura Joszt, MA
The top biosimilars content of 2022 reviewed perceptions around switching to a trastuzumab biosimilar, drug costs, and the successful implementation of biosimilars in practice.
rendering of a molecule
December 14th 2022

Tocilizumab Biosimilars Show Similar Safety, Tolerability, Immunogenicity to Reference: ACR Abstracts

Laura Joszt, MA
Abstracts presented at the annual meeting of the American College of Rheumatology (ACR) show 2 tocilizumab biosimilars were comparable to the reference product.
<12345678
...
18>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences™ and AJMC®.
All rights reserved.

About Us
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo